Penumbra Inc. stock trades near 317 dollars as investors weigh growth and valuation

Penumbra, Inc. stock (ISIN US70975L1070) is trading around USD 317.60 on the New York Stock Exchange as of September 19, 2026, leaving the medical device specialist near levels that reflect strong growth expectations from investors. Per data cited up to September 19, 2026, the shares have delivered a notable double-digit performance over the past twelve months, underlining sustained interest in the company’s neurovascular and vascular product portfolio.

Stock hovers above modeled fair value

According to Faircurve on September 19, 2026, Penumbra, Inc. is listed in a sector overview at a last close of USD 317.60 with a modeled fair value of USD 283.93, implying the shares trade about 10.6% above that fair value estimate at a market capitalization of roughly USD 12.5 billion. This quantified gap indicates that, within that model, the current price embeds a premium relative to intrinsic value calculations, which investors may see as justified by growth prospects but which also narrows the margin of safety.

A separate overview of Penumbra Inc. stock published on September 19, 2026 notes that the stock price around USD 315.79 on the New York Stock Exchange corresponds to a one-month performance of 5.98% and a one-year performance of 31.73%, based on data up to that date, with a market capitalization of about USD 12.37 billion and classification within the healthcare and medical devices segment on the large-cap side. In that context, Penumbra’s share price has moved roughly one third higher over the past year, a gain that comfortably exceeds inflation and many broad market indices over the same period.

Valuation context and growth expectations

The Faircurve sector study assigns Penumbra, Inc. a quality score of 59 out of 100 and describes the stock as fairly valued despite the 10.6% premium to its modeled fair value, suggesting that, in the view of that quantitative framework, the company’s fundamentals and growth profile reasonably support the current valuation level. For investors, the combination of a roughly USD 12.5 billion market capitalization and a price modestly above model fair value signals that the market already prices in significant expectations for continued revenue and earnings expansion.

The recent performance metrics highlighted in the Penumbra Inc. stock overview, with a 5.98% price increase over the latest month and a 31.73% rise over the latest year, as of September 19, 2026, reinforce this interpretation by showing that the majority of that valuation premium was built through sustained gains rather than a single short-lived spike. Historically, gains of more than 30% over twelve months in a large-cap medical devices stock often reflect a mix of product launch momentum, geographic expansion and potential margin improvements, even if the precise revenue and earnings figures for Penumbra’s most recent quarter are not detailed in the available sources.

Stock level and investor perspective

As of September 19, 2026, Penumbra, Inc. stock is quoted at around USD 317.60 on the New York Stock Exchange, corresponding to a market capitalization in the area of USD 12.5 billion and a recent one-year performance of approximately 31.73%. With the shares trading about 10.6% above the modeled fair value of USD 283.93 in the Faircurve framework, investors face a trade-off between paying a valuation premium and gaining exposure to a medical device company that has recently delivered strong price momentum and sits firmly in the large-cap healthcare segment.

More news and analyses on Penumbra, Inc. stock